

Medicinal Chemistry

The Role of Organic Chemistry in Drug Research

Second edition

edited by

C. R. Ganellin

*Department of Chemistry, University College London,
London, U.K.*

and

S. M. Roberts

*Department of Chemistry, University of Exeter,
Exeter, U.K.*



Academic Press

Harcourt Brace Jovanovich, Publishers
London San Diego New York Boston
Sydney Tokyo Toronto

Contents

Contributors	ix
Preface	xi
Glossary	xiii
1. Introduction to Receptors and the Action of Drugs	1
S. M. Roberts	
I. Communication between Cells: The Roles of Receptors and Enzymes	1
II. Neurotransmitters, Receptors and the Nervous System	7
III. Enzymes and Enzyme Inhibitors	13
IV. Other Types of Bioactive Molecules	14
V. Factors Influencing Drug Action	14
Additional Reading	17
2. Structure and Catalytic Properties of Enzymes	19
M. G. Davis	
I. Configuration of Enzymes	19
II. Enzyme Specificity, Classification and Nomenclature	22
III. Characteristics of Enzyme Catalysis	23
IV. Enzyme Reaction Rates	25
V. Enzyme Substrates as Drugs	28
VI. Enzyme Inhibition and Enzyme Inhibitors as Drugs	29
VII. Enzyme Regulation	33
Additional Reading	36
3. Receptor Pharmacology	37
A. J. Gibb	
I. Introduction	38
II. Bioassay and the Measurement of Drug Effects	39
III. Quantifying Drug-Receptor Interactions	41
IV. The Hill Equation	43
V. Radioligand-binding Studies – A Direct Measure of Occupancy	43
VI. Receptor Structure	45
VII. Relating Occupancy to Response	48
VIII. Competitive Antagonism and the Schild Equation	52
IX. Desensitization and the Control of Receptor Number	53
X. Partial Agonists and Agonist Efficacy	55
XI. Conclusions	58
References	59

4. Drug Access and Prodrugs	61
A. J. Collis	
I. Preface	61
II. Drug Access	62
III. What To Do in the Event of Failure	67
IV. Design of Prodrugs	70
V. Summary	80
Suggested Reading	81
References	81
5. QSAR and the Role of Computers in Drug Design	83
E. G. Maliski and J. Bradshaw	
I. Introduction	84
II. QSAR in the Drug Discovery Process	84
III. Applications Related to Biological Processes	86
IV. Applications Related to the Drug Discovery Process	89
V. Interpretation	94
VI. Summary	99
VII. Further Explanation of Terminology	100
References	101
6. The Current Status and Future Impact of Molecular Biology in Drug Discovery	103
T. J. R. Harris	
I. Introduction	103
II. Protein Therapeutics	104
III. Protein Engineering	108
IV. Protein Structure Determination	109
V. Peptides as Drugs	111
VI. Receptor Structure and Function	112
VII. Novel Assays and Screens	114
VIII. Molecular Basis of Disease	116
IX. Affecting the Genes Themselves	118
X. Transgenic Animals	119
XI. Conclusions	119
References	120
7. General Approaches to Discovering New Drugs: An Historical Perspective	121
C. R. Ganellin	
I. Introduction	121
II. Natural Products as a Source for New Drugs	122
III. Existing Drugs as a Basis for New Drugs	123
IV. Disease Models as Screens for New Drugs	127
V. Physiological Mechanisms; The Modern 'Rational Approach' to Drug Design	128
VI. Uncertainties in Drug Design and Development	136
References	139

8. Discovery and Development of Cromakalim and Related Potassium Channel Activators	141
G. Stemp and J. M. Evans	
I. Introduction	142
II. Discovery of Cromakalim	142
III. Structure–Activity Studies	145
IV. Mode of Action of Cromakalim	150
V. Recent Developments	152
VI. Therapeutic Potential of Potassium Channel Activators	159
VII. Conclusion	161
References	161
Further Reading	162
9. Angiotensin-Converting Enzyme (ACE) Inhibitors and the Design of Cilazapril	163
S. Redshaw	
I. Introduction	163
II. The Renin–Angiotensin System	164
III. Proteolytic Enzymes	166
IV. ACE and the Metalloproteinases	168
V. Assays for ACE	169
VI. The Design of ACE Inhibitors	169
VII. Biological Properties of ACE Inhibitors	183
VIII. Conclusions	184
References	184
10. Beta Blockers	187
B. G. Main and H. Tucker	
I. Introduction	188
II. Nervous Control of the Heart and Circulation	188
III. Nature of the β -Receptor	190
IV. β -Blockade and Cardiac Disease	191
V. Early β -Blockers	192
VI. Pharmacology of β -Blockers	194
VII. Structure–Activity Relationships of Early β -Blockers	195
VIII. Cardioselective β -Blockade	196
IX. Structure–Activity Relationships of Cardioselective β -Blockers	197
X. β_2 -Selective Blockade	198
XI. 'Third Generation' β -Blockers	201
XII. Chemistry of β -Blockers	202
XIII. Clinical Effects of β -Blockers	205
XIV. Side Effects of β -Blockers	206
XV. Conclusion	207
References	207
Reviews	208

11. Salbutamol: A Selective β_2-Stimulant Bronchodilator	209
L. H. C. Lunts	
I. Introduction and Biological Background	209
II. Biological Test Procedures	211
III. Structure–Activity Relationships and Metabolism of Catecholamines	212
IV. Chemical Approach to Finding an Alternative β -Stimulant	213
V. Structure–Activity Relationships between Salbutamol and Congeners	217
VI. Summary and Final Comments	225
VII. Progress beyond Salbutamol	225
References	226
12. Discovery of Cimetidine, Ranitidine and Other H_2-Receptor Histamine Antagonists	228
C. R. Ganellin	
I. Background Rationale	228
II. The Search for a Histamine Antagonist	232
III. Cimetidine, a Breakthrough in the Treatment of Peptic Ulcer Disease	246
IV. Furan in place of Imidazole; The Discovery of Ranitidine	248
V. Discovery of Tiotidine and Famotidine	251
VI. Other Compounds	253
References	254
13. Fluconazole, An Orally Active Antifungal Agent	257
K. Richardson	
I. Introduction	257
II. Approach and Mechanism of Action	259
III. Chemistry and Structure–Activity Relationships	260
IV. Clinical Studies	265
V. Conclusions	270
Additional Reading	271
References	271
14. Clavulanic Acid and Related Compounds: Inhibitors of β-Lactamase Enzymes	273
A. G. Brown and I. François	
I. Introduction	274
II. Isolation of Clavulanic Acid	276
III. Biological Activity of Clavulanic Acid	279
IV. Chemistry of Clavulanic Acid and Biological Activity of Some Derivatives	284
V. Mechanism of Action of Clavulanic Acid	288
VI. The Olivanic Acids and Thienamycins	291
VII. Conclusion	292
References	292
Index	295